GlobeNewswire Inc | Sep 1, 2021 04:05PM EDT

September 01, 2021

CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate in two upcoming virtual investor conferences.

Events:

Morgan Stanley Virtual Annual Global Healthcare ConferenceFormat: Fireside Chat and investor 1x1 meetingsThursday, September 9, 202111:45am ETPlease find a link to the presentation here. A replay will be available for 90 days.

H.C. Wainwright 23rd Annual Global Investment Conference Format: Presentation and investor 1x1 meetingsMonday, September 13, 2021All company presentations will be available on-demand beginning at 7:00am ETPlease find a link to the presentation here.

A webcast of both presentations can also be accessed under Events & Presentations in the Investors section of the Companys website, www.foghorntx.com

About Foghorn Therapeutics

FoghornTherapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Controlplatform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

Media Contact:

Fanny Cavali, Foghorn Therapeutics Inc.fcavalie@foghorntx.com

Gregory Kelley, Ogilvygregory.kelley@ogilvy.com

Investor Relations Contact:

Ben Strain, Foghorn Therapeutics Inc.bstrain@foghorntx.com

Hans Vitzthum, LifeSci Advisors617-430-7578hans@lifesciadvisors.com